Inhibikase Therapeutics reports $4.6 million net loss for Q1 2024, positive developments in trials.

From GlobeNewswire: 2024-05-15 20:00:00

Inhibikase Therapeutics, Inc. reported financial results for Q1 2024, showing a net loss of $4.6 million. Key developments include a Phase 2 201 trial for Risvodetinib in Parkinson’s disease, 83% enrolled as of May 10. Positive interactions with the FDA for IkT-001Pro in cancer and cardiopulmonary disease are ongoing.

The company aims to complete enrollment for the 201 trial of Risvodetinib in Q2 2024, with 99 participants enrolled as of May 10. Topline data results are expected in the second half of 2024. In addition, Inhibikase plans to initiate a 12-month extension study of risvo, pending resources.

Inhibikase completed a Pre-NDA meeting with the FDA for IkT-001Pro in oncology on February 12, 2024. The Company is considering studying the 1200 mg dose of IkT-001Pro and conducting an analysis comparing IkT-001Pro and imatinib mesylate in gut absorption. Milestone-based meetings will be requested as the NDA process advances.

A completed Pre-IND meeting was held with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension on April 5, 2024. Final Meeting Minutes on May 3, 2024 confirmed FDA support for IkT-001Pro as a possible treatment for PAH. A pre-clinical hERG study in comparison to imatinib is planned for the current quarter.



Read more at GlobeNewswire:: Inhibikase Therapeutics Reports First Quarter Financial